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G protein-coupled receptors (GPCRs) mediate the perception of
smell, light, taste, and pain. They are involved in signal recognition
and cell communication and are some of the most important
targets for drug development. Because currently no direct struc-
tural information on high-affinity ligands bound to GPCRs is
available, rational drug design is limited to computational predic-
tion combined with mutagenesis experiments. Here, we present
the conformation of a high-affinity peptide agonist (neurotensin,
NT) bound to its GPCR NTS-1, determined by direct structural
methods. Functional receptors were expressed in Escherichia coli,
purified in milligram amounts by using optimized procedures, and
subsequently reconstituted into lipid vesicles. Solid-state NMR
experiments were tailored to allow for the unequivocal detection
of microgram quantities of 13C,15N-labeled NT(8–13) in complex
with functional NTS-1. The NMR data are consistent with a disor-
dered state of the ligand in the absence of receptor. Upon receptor
binding, the peptide undergoes a linear rearrangement, adopting
a -strand conformation. Our results provide a viable structural
template for further pharmacological investigations.
G protein-coupled receptors (GPCRs) are integral mem-brane proteins involved in a number of important physio-
logical processes, including sensory transduction, mediation of
hormonal activity, and cell-to-cell communication (for reviews,
see refs. 1 and 2). More than 1,000 different GPCRs have been
identified, and many of them have been implicated as major
therapeutic routes to the treatment of human diseases (3).
Despite the striking clinical relevance of GPCRs, only one
high-resolution structure (rhodopsin) is available (4, 5). The
diversity among endogenous GPCR ligands is exceptional. Small
molecule ligands such as biogenic amines have been proposed to
bind within the hydrophobic core of their respective receptors.
In contrast, mutational mapping of ligand-binding sites in pep-
tide receptors indicates that extracellular domains are also
involved in ligand recognition (2). To date, direct structural
information regarding ligand binding and GPCR activation is
very limited (6). Targeted drug design is restricted to compu-
tational methods and other ligand design approaches to find and
optimize lead compounds (7). The precise knowledge of recep-
tor-bound ligand structures would substantially aid the devel-
opment of tailor-made medicines.
Neurotensin (NT) is a 13-aa peptide (8) that is involved in a
variety of neuromodulatory functions in the central and periph-
eral nervous system (9). NT binds to its GPCRs, NT type I
receptor (NTS-1) and NTS-2 (10–13). The levocabastine-
insensitive NTS-1 (10–12) interacts with the agonist NT with
high (i.e., subnanomolar) affinity. Similar observations were
made for the N-terminally truncated form of rat NTS-1 when
expressed as a maltose-binding protein (MBP) fusion in Esch-
erichia coli (14, 15) and purified in the presence of detergents
(14, 16). Notably, not only the full-length peptide, but also the
C-terminal part of NT, NT(8–13), has been found to interact
with NTS-1 with high affinity (see, for example, refs. 11 and 17).
The high affinity of the ligand to its receptor has precluded the
elucidation of the receptor-bound ligand conformation by solu-
tion-state NMR (see, for example, ref. 6). A recent NMR study
in the presence of detergent reported NT(8–13) chemical shift
changes upon receptor interaction (18, 19). However, the mode
of NT binding to its GPCR NTS-1 remains unknown.
Solid-state NMR (ssNMR) spectroscopy provides a means of
studying conformational changes of ligands upon binding to
high-affinity receptors in a noncrystalline environment. Only the
relative size of ligand and natural abundance background (NAB,
including receptor, lipids, etc.) determine whether the signal of
the bound ligand can be detected unequivocally. For example,
simple 13C isotope labeling has been sufficient for structural
investigations of membrane proteins (20–22) or peptideprotein
complexes (23) where ligandNAB 102.
Double-quantum filtering (2QF, see, for example, refs. 24 and
25) permits the extension of this size limit to ligandNAB104
and hence allows for the study of NT(8–13) (1 kDa)NTS-1 (101
kDa) binding in a detergentlipid environment. As shown pre-
viously by ssNMR experiments and ab initio calculations (26), the
resulting resonance frequencies are not only diagnostic for each
individual peptide residue (27, 28), but they are also very
sensitive to polypeptide backbone conformation (27, 29–34). As
we will show below, extending 2QF spectroscopy into two
spectral dimensions and the study of a uniformly labeled version
of NT(8–13) enables the derivation of the backbone structure
from a single NMR experiment.
Our study hence involves (i) the optimization of 2D 2QF
(13C,13C) correlation spectroscopy and (ii) a subsequent NMR
chemical shift analysis. The structure of free, immobilized NT,
and the conformational rearrangements associated with recep-
tor binding are studied at atomic resolution, providing unam-
biguous information about a high-affinity ligand in receptor-
bound form.
Materials and Methods
Preparation of 13C,15N-Labeled NT(8–13). The uniformly 13C,15N-
labeled hexapeptide Ac-Arg-Arg-Pro-Tyr-Ile-Leu-OH
([13C,15N]-NT(8–13)) (Fig. 1) was prepared via solid-phase
9-fluorenylmethoxycarbonyl (Fmoc) chemistry on a Wang resin
(74 mol scale) with benzotriazol-1-yloxytris(dimethylamino)
phosphonium hexafluorophosphate1-hydroxybenzotriazole ac-
tivation by using an ABI 433A (Applied BiosystemsPerkin–
Elmer) peptide synthesizer (for a review on Fmoc chemistry, see
e.g., ref. 35). All isotope-labeled amino acid derivatives were
Abbreviations: Fmoc, 9-fluorenylmethoxycarbonyl; GPCR, G protein-coupled receptor;
MAS, magic angle spinning; MBP, maltose-binding protein; NAB, natural abundance
background; NT, neurotensin; NTS-1, NT type I receptor; ssNMR, solid-state NMR; 1Q, single
quantum; 2QF, double-quantum filtering.
§Present address: AstraZeneca R&D Mo¨lndal, Pepparedsleden 1, 431 83 Mo¨lndal, Sweden.
To whom correspondence should be addressed. E-mail: rkgriss@helix.nih.gov or maba@
nmr.mpibpc.mpg.de.
© 2003 by The National Academy of Sciences of the USA
10706–10711  PNAS  September 16, 2003  vol. 100  no. 19 www.pnas.orgcgidoi10.1073pnas.1834523100
purchased from Cambridge Isotope Laboratories (Andover,
MA). Loading of Fmoc-[U-13C,15N]-Leu-OH (1.9 eq) on the
resin was accomplished manually by means of N,N-diisoprop-
ylcarbodiimide4-dimethylaminopyridine-assisted coupling.
Small or no excess of the amino acid building blocks was used in
the peptide coupling steps, i.e., 1.9 eq Fmoc-[U-13C,15N]-Ile-OH,
2 eq Fmoc-[U-13C,15N]-Pro-OH, 1.6 eq Fmoc-[U-13C,15N]-
Tyr(OtBu)-OH, and 1 eq Fmoc-[U-13C,15N]-Arg(Pmc)-OH. The
coupling time was 2 h. The peptide was cleaved from the resin
with the following reagents: 120 l of 1,2-ethanedithiol, 120 l
of triisopropylsilane, 80 l of H2O, 80 mg of phenol, and 9.6 ml
of trif luoroacetic acid (TFA) (for general TFA-cleavage proto-
col see ref. 36). The crude peptide was purified with RP-HPLC
on an Alltima C18 column (10  250 mm, 5-m particles,
AllTech Associates) applying a gradient of acetonitrile in 0.1%
aqueous TFA. The lyophilized 13C,15N-labeled hexapeptide was
obtained in 40% yield (34.3 mg). In addition, the 13C,15N-labeled
pentamer Ac-Arg-Pro-Tyr-Ile-Leu-OH [NT(9–13)], which re-
sulted from incomplete coupling of the last amino acid, could be
readily isolated by RP-HPLC in 14% yield (9.1 mg). For NMR
experiments with solid-phase [13C,15N]-NT(9–13), 2 mg of the
lyophilized peptide was loaded into a 4-mm magic angle spinning
(MAS) rotor. To reduce sample heterogeneity, 1 l of distilled
water was added. For NMR experiments with solid-phase
[13C,15N]-NT(8–13), 0.1 mg of the peptide was dissolved in
detergent-containing buffer [25 mM TrisHCl, pH 7.45% glyc-
erol1 mM EDTA50 mM NaCl0.1% n-dodecyl--D-
maltoside0.2% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate0.04% cholesteryl hemisuccinate] and placed
into the MAS rotor.
Purified, Detergent-Solubilized NTR Sample (NTS-1A). The NTS-1
fusion protein MBP-rT43NTR-thioredoxin (TrxA)-H10 (Fig. 1)
consisted of the E. coli MBP, followed by the N-terminally
truncated rat NTS-1 (rT43NTR), the E. coli TrxA, and a
decahistidine tail (H10) (37). The receptor fusion protein was
expressed in functional form in E. coli (37) (50 liters) and
purified at large scale (two purifications) in the presence of the
detergents n-dodecyl--D-maltoside and 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonate, and cholesteryl hemisuc-
cinate, by immobilized metal affinity chromatography (60-ml
Ni-NTA column), followed by a 10-ml NT column and anion
exchange chromatography (5-ml HiTrap Q-Sepharose column),
as described for the human NTS-1 fusion protein MBP-huNTR-
TrxA-H10 (38). The Q-Sepharose eluate was concentrated by
using a Centriprep-30 device (Amicon, 2.9 mg of functional
receptor fusion protein available after concentration) and stored
in liquid nitrogen. In preparation for the NMR experiments, the
concentrated NTS-1 fusion protein was diluted with detergent-
containing buffer to give final concentrations of 25 mM TrisHCl
(pH 7.4), 5% glycerol, 1 mM EDTA, and 50 mM NaCl. The
receptor was concentrated at 3°C by using Ultrafree-15 Millipore
MWCO 50K and Microcon YM-30 (Amicon) devices. Protein
determination (39) and [3H]NT binding analysis (16) of the
concentrated sample gave a value of 7,563 pmolmg (565 l at
3.68 mgml). A theoretical value of 10,361 pmolmg is calculated
for MBP-rT43NTR-TrxA-H10 (molecular mass of 96.5 kDa),
assuming one ligand binding site per receptor molecule. Seventy
three percent of the concentrated receptor preparation hence
binds agonist. 13C,15N-labeled NT(8–13) (molecular mass of 973
Da) (2.3 g) was then added to the receptor preparation (0.37
mg) [agonistreceptor ratio of 0.6 (MM), based on total protein
content] and incubated for 2 h on ice. The [13C,15N]-NT(8–13)
receptor sample (100 l) was placed into a 4-mm MAS rotor,
frozen on dry ice, and subjected to NMR analysis. To titrate the
amount of bound agonist, an additional 10 g of [13C,15N]-
NT(8–13) was added to the receptor preparation and analyzed.
Sample NTNTS-1A contains in total 0.37 mg of receptor
protein and 12.3 g of [13C,15N]-NT(8–13) [agonistreceptor
ratio of 3.3 (MM), based on total protein content]. Consider-
ation of the ligand binding data gives an agonistfunctional
receptor ratio of 4.5 (MM) in the sample NTNTS-1A.
Lipid-Reconstituted NTR Sample (NTS-1B). The NTS-1 fusion protein
MBP-N10-Tev-T43NTR-N5G3S-Tev-G3S-TrxA-H10 is shown
schematically in Fig. 1. The receptor fusion protein was ex-
pressed in functional form in E. coli (90 liters) and purified
(50-ml Ni-NTA column, followed by a 10-ml NT column; 5.2 mg
of purified protein from three purifications). For reconstitution
into lipid vesicles, receptors (final concentration of 0.13 mgml)
were incubated with n-dodecyl--D-maltoside-saturated brain
polar lipids [Avanti Polar Lipids, final concentration of 0.4
mgml, lipid-to-receptor ratio of 400 (MM)] for 4–5 h at 4°C
in a volume of 13 ml, followed by the addition of Bio-beads SM-2
(BioRad, 1.5 gram). The Bio-beads were exchanged four times
over a time period of 3 days. Proteoliposomes were recovered by
ultracentrifugation and resuspended in 50 mM TrisHCl, pH
7.41 mM EDTA at a protein concentration of 2–2.5 mgml. We
estimated from [3H]NT binding assays (40) that 66% of the
reconstituted receptors are accessible to ligand, with the remain-
ing receptors either not binding agonist or having their ligand
binding sites facing inside the lipid vesicles (data not shown). For
the NMR experiments, 22 g of [13C,15N]-NT(8–13) was added
to 3.8 mg of reconstituted receptor fusion protein (molecular
mass of 101 kDa) [agonistreceptor ratio of 0.6 (MM), based on
total protein content]. After incubation (4 h, 4°C), the sample
(NTNTS-1B) was centrifuged at 40,000 rpm (70 Ti rotor) for 30
min and loaded as a pellet into a 4-mm MAS rotor. Consider-
ation of the ligand binding data gives an agonistfunctional
receptor ratio of 0.9 (MM) in the sample NTNTS-1B.
ssNMR Experiments and Analysis. All NMR experiments were
performed on a wide-bore, 600-MHz (1H resonance frequency,
Bruker Biospin, Rheinstetten, Germany) spectrometer by using
double (1H,13C) or triple (1H,13C,15N) resonance MAS (41)
probe heads. Experiments on solid-phase [13C,15N]-NT(9–13)
samples were conducted at 5°C, whereas experiments involving
bufferprotein solutions and reconstituted sample NTNTS-1B
were performed at 80°C or 85°C. An MAS spinning rate of
7 kHz was used with TPPM decoupling (42) at 110-kHz radio-
frequency amplitude during free evolution and detection peri-
ods. Cross polarization (43, 44) experiments involved amplitude
modulated radio-frequency fields (45). 2QF experiments were
performed by using the POST-C7 (46) dipolar recoupling
scheme with 32-step phase cycling scheme to suppress unwanted
single-quantum (1Q) signals (see Fig. 5, which is published as
supporting information on the PNAS web site, www.pnas.org).
Fig. 1. (Upper) Sequences of NT, NT(8–13), and NT(9–13) in single-letter
code. (Lower) Schematic representation of the NT receptor fusion proteins.
Amino acids in single-letter notation are given in gray; subscripts stand for
repetition.







These phase cycles were tested by performing 2QF experiments
in the side-chain region of the natural abundance tri-peptide
Ala-Gly-Gly. Results of the 1D experiments with the four
preparations (see below) containing uniformly 13C,15N-labeled
NT peptides are given in Figs. 6 and 7, which are published as
supporting information on the PNAS web site. Additional test
experiments on mixtures of labeled and unlabeled amino acids
confirmed the suppression of 1Q signals by at least a factor of 100
in the 2Q spectra in line with the theoretical expectation. As a
result, microgram peptide quantities can be reliably detected in
the presence of a large background signal. Details for the
presented 2D correlations experiments are given in the figure
legends and Fig. 5. Further information regarding the discussed
data interpretation is given in Fig. 8, which is published as
supporting information on the PNAS web site.
For the construction of the backbone model, the TALOS (47)
package was used. As recently demonstrated in the context of
fibrous peptides (30, 33, 34), TALOS analyses NMR chemical
shifts assignments of three consecutive peptide residues by using
a statistical homology search to arrive at an estimation of the
dihedral angles of the peptide of interest. Within this framework,
backbone dihedral angles of NT(8–13) can be obtained for
residues Arg-9–Ile-12 (see Table 1, which is published as sup-
porting information on the PNAS web site). For each residue,
80% of the predicted dihedral angles sets are consistent with
an elongated peptide conformation. Additional information
regarding  of Arg-8 and  of Leu-13 is accessible from
considering an extended sequence Pro-7-NT(8–13)-X, where
Pro-7 corresponds to the residue of the full-length agonist NT
and X is varied. This approach predicts  (Arg-8)  34  15°
and  (Leu-13)  104  16° for X  Ala, Pro, Thr.
Results
Four preparations containing uniformly 13C,15N-labeled NT
peptides (see Fig. 1) were analyzed by ssNMR: (i) solid-phase NT
(9–13) as a spectroscopic reference [this pentapeptide, in con-
trast to NT(8–13), binds to NTS-1 with low affinity only (17)],
(ii) NT(8–13) in detergent-containing buffer to investigate the
structure of the free ligand, (iii) NT(8–13) in complex with the
purified, detergent solubilized receptor (sample NTNTS-1A),
and (iv) in complex with lipid-reconstituted NTS-1 (sample
NTNTS-1B). The latter samples allow us to determine the
conformation of NT(8–13) when bound to its GPCR with high
affinity. To do so, NMR signals arising from microgram quan-
tities of peptide ligand must be detected in the presence of large
background signals (NAB) resulting from buffer components
(glycerol) and detergents (sample NTNTS-1A) or lipid (sample
NTNTS-1B). Because ligandNAB 102, conventional 1Q
experiments are not suitable to probe ligand binding in the
current context (see Fig. 6). Instead, 2QF (see, for example, refs.
24 and 25) methods that select for pairs of nearby 13C-13C nuclei
(e.g., directly bonded) are mandatory. Measurements on the
purified NTS-1 fusion protein (0.27 mg of functional receptor)
in the presence of increasing amounts of NT(8–13) in microgram
quantities gave 2Q signals that changed upon agonist addition
(data not shown), reflecting adequate sensitivity of our 2QF
experiments. For the spectral identification of the individual
peptide residues and the subsequent side-chain 13C resonance
assignment, 2D 2QF correlation experiments are compulsory
and are discussed below.
Immobilized NT in the Absence of Receptor. Fig. 2 contains results
of a 2D 13C-13C 2QF correlation experiment for free NT(9–13)
and NT(8–13) in detergent solution. The observed 2D patterns
agree well with standard correlation maps (32, 48) expected
from the NT amino acid sequence. The observed (1Q) line width
varies between 1 and 2.5 ppm and amounts to 1.5 ppm for the
majority of the observed correlations. For sensitivity reasons,
results of Figs. 2b and 3 (see below) were obtained by using a
smaller number of t1 increments. As a result, the 2Q line width
is enlarged but does not affect the spectral analysis presented
here. If rare-spin polarization transfer is used, inter- and intra-
Fig. 2. 2D 13C-13C (2Q,1Q)-correlation experiments for 2 mg of solid-phase [13C,15N]-NT(9–13) (a) and 0.1 mg of frozen [13C,15N]-NT(8–13) in detergent solution
(b). In a and b, 128 and 44 t1 experiments, respectively, were recorded by using TPPM (42) decoupling (at a radio-frequency amplitude of 110 kHz) in evolution
and detection periods. Residue assignments are given in single-letter notation; intraresidue side-chain correlations are indicated in a. POST-C7 recoupling was
used for 2Q excitation and reconversion. Data shown result from 256 (a) and 1,536 (b) scans. Below each 2D correlation spectrum, secondary chemical shifts 	
as obtained from Table 1 are given. (b) Arg-8 and Arg-9 	 values are shaded to indicate that secondary chemical shifts here are only tentatively assigned (see
also Fig. 3).
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residue correlation experiments are in general necessary to
unambiguously assign the NMRs of larger polypeptides under
MAS conditions (48).
In the (2Q,1Q) correlation experiment considered here, res-
onance frequencies of two dipolar coupled spins detected in the
1Q dimension (1QC) must resonate at the sum frequency along
the 1 (2QC) axis. Hence, knowledge of the characteristic 13C
chemical shifts of the five [NT(9–13)] or six [NT(8–13)] involved
residues and construction of the corresponding standard 2D 2Q
correlation map (48) is sufficient to assign resonances for all
residues in the spectrum (see also Fig. 8). In particular, all
backbone [((C) 
 (C), (C,)] correlations are easily
identified (see Table 1). Knowledge of the isotropic chemical-
shift values can be used to interpret the observed spectra in terms
of a 3D backbone conformation of NT(9–13) and NT(8–13). For
this purpose, we can calculate the parameter 	 that reflects the
conformation-dependent chemical shift of C and C resonances
(32) and relates the experimentally observed carbon chemical
shifts under MAS conditions to standard, isotropic random coil
values (see BioMagResBank, a repository for data from NMR
spectroscopy on proteins, www.bmrb.wisc.eduindex.html).
These parameters are plotted in Fig. 2 for the C-terminal
residues of NT. In particular, negative values of 	 are consistent
with large positive values of the backbone dihedral angle ,
whereas 	  0 is indicative of helical (i.e.,   0) peptide
backbone conformations (32).
From Fig. 2, we find that secondary chemical shifts for free
NT(9–13) and NT(8–13) exposed to detergent-containing
buffer are in general small and vary in sign. Significant changes
in 	 between both preparations are detected for Pro-10, Ile-12,
and Leu-13. From the homonuclear correlation experiment in
Fig. 2b we cannot, a priori, assign the Arg side-chain correlations
to either Arg-8 or Arg-9. For this reason, Arg-8 and Arg-9 	
values are shaded in Fig. 2b. Notably, the Arg assignment
obtained for NT(9–13) matches one set of (C, C) Arg chemical
shifts detected in all other considered preparations (see below).
Therefore, the corresponding correlations in Figs. 2b and 3 were
tentatively assigned to Arg-9. Irrespective of this ambiguity, we
conclude from the data presented in Fig. 2 that NT(9–13) and
NT(8–13) remain largely unstructured in the absence of the
receptor.
NTNTR Complex. Next, we investigated the interaction of NT(8–
13) with purified NTS-1 in detergent solution (sample NTNTS-
1A) (Fig. 3a). The ratio of agonistfunctional receptor in sample
NTNTS-1A is 4.5 (MM). Under these experimental condi-
tions, we expect signal contributions from both free and recep-
tor-bound NT(8–13). In line with 1D results (see Figs. 6 and 7),
we observe in the 2D 2QF experiment broad signals 60 and 30
ppm in 1 and 2, respectively. These signals most likely stem
from natural abundance 2Q contributions of the detergents and
other buffer components. On the other hand, well-separated
side-chain resonances and the (C, C) correlations of interest lie
outside this range and can be identified (Table 1). Again, these
resonance assignments do not permit discriminating between
Arg-8 and Arg-9 but they can be used to define conformation-
dependent chemical shifts 	 summarized in Fig. 3a. Except for
Leu-13, all residues are now described by negative values of 	.
The interpretation of Fig. 3a in terms of secondary chemical
shifts is not only influenced by the occurrence of strong detergent
and buffer signals, but also by a relatively low NT(8–13) signal
intensity as a consequence of the limited amount of purified
receptor in the NMR rotor. To increase the amount of functional
receptor and hence the amount of bound NT(8–13) for ssNMR
measurements, and to reduce the noise contributions from deter-
gent and buffer components, the NTS-1 fusion protein was recon-
stituted into lipid, which allows for packing of the receptor at higher
density (2.5 mg of functional receptors) into the NMR rotor. As a
result, the amount of NT(8–13) (22 g) could be significantly
increased (sample NTNTS-1B). At a peptidereceptor molar ratio
of 0.9, we can assume that the ssNMR signals must predominantly
result from bound NT(8–13) molecules. Fig. 3b (red) shows a 2Q
Fig. 3. 2D 13C-13C (2Q,1Q) correlation experiments for the two [13C,15N]-NT(8–13)receptor preparations NTNTS-1A (a) and NTNTS-1B (b, in red). In both cases,
32 t1 experiments were recorded by using TPPM (42) decoupling in evolution and detection periods. Residue assignments are given in single-letter notation. Similar
to Fig. 2, POST-C7 recoupling was used for 2Q excitation and reconversion. (a) A total of 13,568 scans were accumulated for each t1 experiment. (b) A total of
11,136 scans were coadded in t2. Below each 2D correlation spectrum, secondary chemical shifts	 as obtained from Table 1 are given. Arg-8 and Arg-9	 values
are shaded to indicate that secondary chemical shifts here are only tentatively assigned. (b) A 1D slice along the t1 axis (54 ppm, indicated in red) and results from
frozen [13C,15N]-NT(8–13) (see Fig. 2b) are included in black for reference. Additional information is given in Fig. 9, which is published as supporting information
on the PNAS web site.







correlation pattern of the sample NTNTS-1B. Consistent with
additional 1D 2QF (see Fig. 7) experiments, the major part of the
spectrum is free of lipid correlations and the general (2Q,1Q)
correlation pattern for NT(8–13) can be readily identified. In
particular, the detection of virtually all side-chain resonances allows
for an unambiguous identification of Ile-12 and Leu-13 residues.
The resulting (C and C) chemical shift assignments are given in
Fig. 3b (see Table 1).
For reference, results of NT(8–13) in detergent buffer are
included in black in Fig. 3b and reveal that the side-chain
resonances do not significantly change upon receptor binding. In
contrast, one observes that the spectral separation between C
and C resonances diminishes considerably upon receptor bind-
ing. Correspondingly, the conformation-dependent chemical
shifts are strongly negative (see Fig. 3b and Table 1). Remark-
ably, results of Fig. 3 lead to similar secondary chemical shifts,
suggesting that both preparations reflect similar ligand–receptor
interactions.
Discussion
In the following, we discuss the structural implications of our
ssNMR study. In the presence of its receptor NTS-1, the agonist
NT(8–13) changes from a disordered state into a defined
-strand conformation. Our structural model of the receptor-
bound ligand could represent a viable template for 3D pharma-
cophore studies (7).
Comparison of Figs. 2 and 3 allows for a qualitative structural
interpretation of the observed chemical shift variations of NT(8–
13). The size and the sign changes of 	 imply that solid-phase
NT(9–13) and NT(8–13) immobilized in detergent buffer re-
main largely unstructured. Our ssNMR data are hence in
qualitative agreement with previous solution-state NMR studies
of NT in aqueous, methanol, and SDS solutions (49, 50), which
indicated an inherent conformational f lexibility with no discern-
ible elements of secondary structure in water and methanol.
Notably, the observed chemical changes with respect to the
random coil are largest for the Arg-8–Arg-9–Pro-10 segment in
buffer-detergent solution, consistent with previously postulated
charge–charge interactions of the peptide with surrounding
detergent molecules (49). In the same manner, the observed
NMR correlations can be analyzed for NT(8–13) in the presence
of functional NTS-1 (Fig. 3). For both samples NTNTS-1A and
NTNTS-1B, comparable chemical shift changes are observed.
Except for Leu-13, both signal sets indicate negative values of	.
Because of the higher concentration of NT(8–13) and therefore
higher signal-to-noise ratio in our NMR studies on NTNTS-1B
(Fig. 3b), we conclude that the peptide conformation (i.e., also
Leu-13) is described by negative values for secondary chemical
shifts 	. Knowledge of 	 and the peptide amino acid sequence
allow for an estimation of the backbone dihedral angles of
NT(8–13) in the receptor-bound form. For this purpose, the
chemical shift assignments of Fig. 3 were used as entry param-
eters within the TALOS (47) prediction routine. Similar to recent
ssNMR studies on fibrous proteins (33, 34), the resulting dihe-
dral angles can be used to construct a 3D model of the backbone
conformation of receptor-bound NT(8–13), which is shown in
Fig. 4. Our data suggest a -strand conformation of the agonist
bound to NTS-1. The current analysis does not yet permit the
refinement of the side-chain conformations of NT(8–13). For
this reason, all side chains in Fig. 4 are shaded and indicated only
for reference.
Previously published molecular modeling studies (51, 52) of
NT bound to NTS-1 resulted in conflicting information about the
presumed structure of the bound agonist. Pang et al. (51)
predicted a compact conformation of NT(8–13), with a proline
type I turn for the segment Arg-9–Pro-10–Tyr-11–Ile-12. The
corresponding backbone angles (, ) for Pro-10 and Tyr-11
would be given by (60°, 30°) and (90°, 0°), respectively,
contradicting the ssNMR data presented here. More recently,
mutagenesis and structure-activity studies combined with mod-
eling techniques were used to predict the receptor binding site
and the conformation of bound NT(8–13) (52, 53). In this model,
NT(8–13) adopts a linear backbone conformation in qualitative
agreement with our ssNMR results. The receptor-NT(8–13) side
chain contacts proposed by Barroso et al. (52) will be investigated
by additional ssNMR experiments that measure interatomic
distances in the NT(8–13)-receptor complex.
To date, no structural information at the molecular level has
been reported on NT bound to its high-affinity receptor. We
have used 2D ssNMR correlation experiments to elucidate the
interaction of NT(8–13) with the rat NTS-1. The observed
chemical shifts not only allow for a comparative study of the NT
conformation in different chemical environments, but also en-
able a direct interpretation of the NMR signals in terms of the
local backbone conformation of the neuropeptide.
Our results on solid-phase NT(9–13) and NT(8–13) immobi-
lized in a detergent environment indicate that the peptide
remains largely unstructured in the absence of the receptor.
When bound to NTS-1, the secondary chemical shifts observed
in the solid state considerably change for most of the amino acid
residues of NT(8–13). The corresponding backbone torsional
angles  are consistent with a strand arrangement of the
agonist in complex with its receptor, both purified and recon-
stituted into lipid. Our selected NMR approach, using chemical
shift information only, was largely dictated by signal-to-noise
considerations. The accuracy of the reported backbone dihedral
angles could be further refined by dipolar double-quantum
dephasing experiments (see, for example, ref. 54) or chemical
shift-selective distance measurements. These experiments along
with additional 15N-13C and CHHC (55) correlation experiments
are ongoing.
The presented ssNMR data provide direct experimental evi-
dence for a distinct conformation of a neuropeptide bound with
high affinity to its GPCR. We have analyzed microgram ligand
quantities in the presence of milligram receptor quantities and
demonstrate that ssNMR experiments are suitable for structural
studies on membrane protein systems for which structural in-
formation at the atomic level is currently lacking.
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